National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection

Clinical Infectious Diseases

Volumn 41, Issue 8, 2005, Pages 1125-1133

  McElroy, Peter D ^a   Ijaz, Kashef ^a   Lambert, Lauren A ^a   Jereb, John A ^a   Iademarco, Michael F ^a   Castro, Kenneth G ^a   Navin, Thomas R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCULATION; CITY; CONFIDENCE INTERVAL; DATA BASE; DEATH; DISEASE SEVERITY; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS; HOSPITALIZATION; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REIMBURSEMENT; REVIEW; SIDE EFFECT; SYMPTOM; TUBERCULOSIS; UNITED STATES;

ANTITUBERCULAR AGENTS; HEALTH SURVEYS; HOSPITALIZATION; HUMANS; LIVER DISEASES; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS; UNITED STATES;

EID: 26444537964     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/444463     Document Type: Review

References (43)

1. Centers for Disease Control and Prevention. Targeted tuberculin skin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000; 49:12-21.
2. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970; 17:28-106.
3. Centers for Disease Control and Prevention. Progress toward tuberculosis elimination in low-incidence areas of the United States-recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 2002; 51:1-14.
4. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-47.
5. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000; 283:1445-50.
6. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786-92.
7. Mwiga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-57.
8. Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127:1296-303.
9. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection-New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:289-91.
10. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations- United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733-5.
11. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51:998-9.
12. Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735-9.
13. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Letter and questionnaire (letter1 and data collection form 1). Available at: http://www.cdc.gov/nchstp/tb/Samples/. Accessed 1 September 2005.
14. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Letter and questionnaire (letter 2 and data collection form 2). Available at: http://www.cdc.gov/nchstp/tb/Samples/. Accessed 1 September 2005.
15. Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 2000. Atlanta, GA: US Department of Health and Human Services, CDC, 2001.
16. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.
17. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972; 106:357-65.
18. Riska N. Hepatitis cases in isoniazid-treated groups and in a control group. Bull Int Union Tuberc 1976; 51:203-8.
19. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991-1001.
20. Franks AL, Binkin NJ, Snider DE, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Reports 1989; 104:151-5.
21. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin-a meta-analysis. Chest 1991; 99:465-71.
22. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494-7.
23. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993; 159:560-4.
24. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996; 164:486-91.
25. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-8.
26. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140:1189-93.
27. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination of pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992; 36:548-51.
28. Gordin FM, Cohn DL, Matts JP, et al. Hepatoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 2004; 39:561-5.
29. Saukkonen J. Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clin Infect Dis 2004; 39:566-8.
30. Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 2002; 288:165-6.
31. Narita M, Kellman M, Franchini D, et al. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection. Chest 2002; 122:1292-8.
32. Bock NN, Rogers T, Tapia JR, et al. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 2001; 119:833-7.
33. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6:995-1000.
34. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137:640-7.
35. Leung CC, Law WS, Chang KC, et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 2003; 124:2112-8.
36. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis. Chest 2003; 123:102-6.
37. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003; 167:824-7.
38. Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004; 39:1764-71.
39. van Hest R, Baars H, Kik S, et al. Hepatotoxicity of rifampin- pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 2004; 39:488-96.
40. Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med 2003; 167:809-10.
41. Institute of Medicine. Ending neglect: The elimination of tuberculosis in the United States. Washington, DC: National Academy Press, 2000.
42. Burman WJ, Reves RR. Hepatotoxicity from rifampin and pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med 2001; 164:1112-3.
43. Blumberg HM. Treatment of latent tuberculosis infection:back to the beginning. Clin Infect Dis 2004; 39:1772-5.